Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Total Non-Current Liabilities (2018 - 2025)

Historic Total Non-Current Liabilities for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $649.1 million.

  • Revolution Medicines' Total Non-Current Liabilities rose 23470.39% to $649.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $649.1 million, marking a year-over-year increase of 23470.39%. This contributed to the annual value of $289.9 million for FY2024, which is 2659.79% up from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' Total Non-Current Liabilities is $649.1 million, which was up 23470.39% from $557.0 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Total Non-Current Liabilities registered a high of $649.1 million during Q3 2025, and its lowest value of $87.6 million during Q1 2021.
  • Over the past 5 years, Revolution Medicines' median Total Non-Current Liabilities value was $144.0 million (recorded in 2022), while the average stood at $206.2 million.
  • As far as peak fluctuations go, Revolution Medicines' Total Non-Current Liabilities tumbled by 830.68% in 2023, and later skyrocketed by 23470.39% in 2025.
  • Over the past 5 years, Revolution Medicines' Total Non-Current Liabilities (Quarter) stood at $134.8 million in 2021, then decreased by 6.19% to $126.4 million in 2022, then surged by 81.11% to $229.0 million in 2023, then grew by 26.6% to $289.9 million in 2024, then soared by 123.9% to $649.1 million in 2025.
  • Its Total Non-Current Liabilities was $649.1 million in Q3 2025, compared to $557.0 million in Q2 2025 and $283.1 million in Q1 2025.